|
May 1
|
Pfizer’s strong Vyndaqel sales draw attention to rare disease drug’s patent life
|
|
Apr 25
|
Will BridgeBio Pharma (BBIO) Report Negative Q1 Earnings? What You Should Know
|
|
Apr 7
|
BridgeBio Pharma Presents Cardiac Magnetic Resonance (CMR) Imaging Evidence Consistent with Clinical Improvement Observed in the ATTRibute-CM Phase 3 Study in Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
|
|
Mar 27
|
TipRanks’ ‘Perfect 10’ List: These 3 Top-Scoring Stocks Are Sending a Bullish Signal
|
|
Mar 6
|
BridgeBio Pharma Announces Pricing of Public Offering of Common Stock
|
|
Mar 5
|
Bayer (BAYRY) Acquires BridgeBio's Cardiovascular Drug
|
|
Mar 4
|
BridgeBio Pharma Announces Proposed Public Offering of Common Stock
|
|
Mar 4
|
BridgeBio Dives After Inking A $310 Million Deal With Bayer For Its Lead Drug
|
|
Mar 4
|
Bayer pays $310M to buy into BridgeBio heart drug
|
|
Mar 4
|
BridgeBio Pharma, Bayer agree on licensing deal for heart disease drug in Europe
|
|
Mar 4
|
BridgeBio Pharma and Bayer Announce European Licensing Agreement for Acoramidis in ATTR-CM
|
|
Feb 2
|
BridgeBio Pharma Shares Positive Results of Single-Arm Phase 3 Study of Acoramidis in Japanese Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Including No Mortality Reported in the Trial at 30 Months
|
|
Jan 30
|
Invitae Partners with BridgeBio Pharma to Harness Genetic Insights for the Discovery of Rare Disease Therapeutics
|
|
Jan 12
|
16 Best Mid-Cap Growth Stocks To Buy Now
|
|
Jan 10
|
BridgeBio Pharma Announces Publication of Positive Results from Phase 3 ATTRibute-CM Study of Acoramidis for Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) in the New England Journal of Medicine
|
|
Jan 3
|
BridgeBio Pharma to Participate in the J.P. Morgan Healthcare Conference
|
|
Dec 26
|
13 High Growth Healthcare Stocks to Buy
|
|
Dec 18
|
3 Russell 2000 Stocks That Are About to Get Absolutely Crushed
|
|
Dec 5
|
12 Most Promising Stocks to Buy According to Hedge Funds
|
|
Dec 5
|
BridgeBio Pharma Announces Submission of New Drug Application (NDA) to U.S. Food and Drug Administration (FDA) for Acoramidis for the Treatment of Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
|